Ozempic vs Wegovy: Key Differences Explained
Ozempic
Semaglutide injection for type 2 diabetes with cardiovascular benefits.
Type 2 diabetic patients seeking improved glucose control with the added benefit of weight loss
Wegovy
GLP-1 receptor agonist approved by FDA specifically for chronic weight management
Obese or overweight individuals (BMI ≥30 or ≥27 with weight-related comorbidities) whose primary goal is significant weight loss
Quick Answer
AI SummaryOzempic and Wegovy are both semaglutide medications but differ primarily in their FDA-approved indication: Ozempic treats type 2 diabetes while Wegovy is approved for chronic weight management in obese or overweight patients. Wegovy uses higher doses and is marketed specifically for weight loss, whereas Ozempic's weight loss is a secondary benefit.
Read full verdictBoth medications contain the same active ingredient (semaglutide) and are highly effective, but serve different primary purposes. Ozempic is the better choice for type 2 diabetes patients seeking diabetes control with weight loss as a bonus, while Wegovy is superior for individuals whose primary goal is significant weight management. Choice should align with medical needs, insurance coverage, and physician guidance.
Was this verdict helpful?
Choose Ozempic if
Best pickType 2 diabetic patients seeking improved glucose control with the added benefit of weight loss
Choose Wegovy if
Obese or overweight individuals (BMI ≥30 or ≥27 with weight-related comorbidities) whose primary goal is significant weight loss
Share this verdict
Track this comparison
Get notified when prices change, new specs ship, or our verdict updates.
Triggers: price change new spec verdict update
No spam. Stop anytime.
Key Differences at a Glance
- Primary FDA Approval:Type 2 Diabetes vs Chronic Weight Management
- Maximum Approved Dose:✓ Wegovy wins(2.4 mg weekly vs 2.0 mg weekly)
- Average Weight Loss:✓ Wegovy wins(15-22% body weight vs 5-7% body weight)
Key Facts & Figures
36 numeric metrics compared
| Metric | Ozempic | Wegovy | Ratio |
|---|---|---|---|
| Monthly Cost (without insurance)(USD) | ~$900 | ~$1,300 | |
| Maximum Weekly Dose(mg) | 2.0 mg | 7.2 mg (HD formulation) | |
| FDA Approval Year | 2017 | 2021 | |
| Number of Dose Strengths Available(strengths) | 4 | 5 | |
| Typical Weight Loss at Maximum Dose(% of body weight) | 5-7% | 15-22% | |
| FDA Approval Year(year) | 2017 (diabetes) | 2021 (weight management) | |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | 25-40% | |
| Injection Frequency(times per week) | 1 | 1 | |
| Average Monthly Cost (Uninsured)(USD) | $900-1,200 | $1,350-1,600 | |
| Time to Maintenance Dose(weeks) | 12 | 16 | |
| HbA1c Reduction in Diabetics(percentage points) | 1.5-2.0 | 0.5-1.0 | |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | — | — |
| A1C Reduction(percentage points) | 1.5-2.0% | — | — |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | — | — |
| Injection Schedule(per week) | Once weekly | — | — |
| Average Retail Price(USD/month) | $900-1,300 | — | — |
| Number of Dose Strengths Available(options) | 3 | — | — |
| Time on Market(years) | 9 years | — | — |
| FDA-Approved Maximum Dose(mg/week) | 1mg weekly | 2.4mg weekly | |
| Average Weight Loss at 52 Weeks (Clinical Trial)(% body weight) | 2-3% reduction (at diabetes doses) | 15-22% reduction | |
| Average Monthly Cost (US, 2026)(USD) | $900-$1,100 | $1,349-$1,550 | |
| Nausea Incidence in Clinical Trials(% of patients) | 10-15% (at 1mg dose) | 25% (at 2.4mg dose) | |
| Insurance Coverage Approval Rate(% of major US insurers) | 85-95% (diabetes indication) | 35-45% (weight loss coverage limited) | |
| Cardiovascular Outcome Reduction (CVOT)(% risk reduction) | 26% MACE reduction (SUSTAIN-6) | Data pending from SELECT trial | — |
| Maximum FDA-Approved Weekly Dose(mg) | 2 mg | 2.4 mg | |
| Average Weight Loss (Clinical Trial)(% body weight) | 5-7% (diabetes indication) | 15% (weight management trials) | |
| Time to Noticeable Weight Loss(weeks) | 8-12 weeks | 4-8 weeks | |
| Average Uninsured Monthly Cost (2024)(USD) | $900-1,200 | $1,300-1,500 | |
| Insurance Coverage Rate (Non-Diabetic Use)(% of plans) | 50-65% (off-label) | 10-20% (excluded as cosmetic) | |
| Active Ingredient Bioequivalence(% identical) | 100% semaglutide | — | — |
| Average Weight Loss at 16 Weeks(lbs) | 5-8 lbs (diabetic patients) | — | — |
| Cardiovascular Event Risk Reduction(%) | 26% (SUSTAIN-6 trial, n=3,297) | — | — |
| Nausea Incidence Rate(%) | 40% at 1.0 mg dose | — | — |
| Average Out-of-Pocket Monthly Cost(USD) | $50-150 (with diabetes insurance) | — | — |
| HbA1c Reduction(percentage points) | 1.5-2.0 points | — | — |
| Clinical Trial Sample Size(participants) | 3,297 (SUSTAIN-6) | — | — |
Sourced from publicly available data ·
Key Differences
8 attributes compared head-to-head
- Type 2 DiabetesPrimary FDA ApprovalChronic Weight Management
- 2.0 mg weeklyMaximum Approved Dose2.4 mg weekly(winner)
- 5-7% body weightAverage Weight Loss15-22% body weight(winner)
- Better for diabetes patients(winner)Insurance CoverageLimited; often out-of-pocket
- $900-1,200(winner)Cost Per Month (2026)$1,350-1,600
- Common but not approvedOff-Label Weight Loss UseOfficially approved(winner)
- Diabetic patientsTarget Patient PopulationObese/overweight individuals
- 12-week titration period(winner)Dosing Schedule16-week titration period
- Primary FDA Approval
Ozempic
Type 2 Diabetes
Wegovy
Chronic Weight Management
- Maximum Approved Dose
Ozempic
2.0 mg weekly
Wegovy
2.4 mg weekly(winner)
- Average Weight Loss
Ozempic
5-7% body weight
Wegovy
15-22% body weight(winner)
- Insurance Coverage
Ozempic
Better for diabetes patients(winner)
Wegovy
Limited; often out-of-pocket
- Cost Per Month (2026)
Ozempic
$900-1,200(winner)
Wegovy
$1,350-1,600
Full Comparison
| Attribute | Ozempic | Wegovy |
|---|---|---|
| Average Weight Loss(% of body weight) | 8-12% | 15-22%(winner) |
| Typical Weight Loss at Maximum Dose(% of body weight) | 5-7% | 15-22%(winner) |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | — |
| A1C Reduction(percentage points) | 1.5-2.0% | — |
| Average Weight Loss at 52 Weeks (Clinical Trial)(% body weight) | 2-3% reduction (at diabetes doses) | 15-22% reduction(winner) |
Show 2 more attributesAverage Weight Loss (Clinical Trial)(% body weight) 5-7% (diabetes indication) 15% (weight management trials) Average Weight Loss at 16 Weeks(lbs) 5-8 lbs (diabetic patients) — | ||
| Monthly Cost (without insurance)(USD) | ~$900 | ~$1,300(winner) |
| Average Monthly Cost (Uninsured)(USD) | $900-1,200(winner) | $1,350-1,600 |
| Average Retail Price(USD/month) | $900-1,300 | — |
| Average Monthly Cost (US, 2026)(USD) | $900-$1,100(winner) | $1,349-$1,550 |
| Average Uninsured Monthly Cost (2024)(USD) | $900-1,200(winner) | $1,300-1,500 |
Show 1 more attributeAverage Out-of-Pocket Monthly Cost(USD) $50-150 (with diabetes insurance) — | ||
| Active Ingredient | Semaglutide | Semaglutide |
| Active Pharmaceutical Ingredient | Semaglutide (recombinant human GLP-1 analog) | Semaglutide (recombinant human GLP-1 analog) |
| Maximum Weekly Dose(mg) | 2.0 mg | 7.2 mg (HD formulation)(winner) |
| FDA-Approved Maximum Dose(mg/week) | 1mg weekly(winner) | 2.4mg weekly |
| Maximum FDA-Approved Weekly Dose(mg) | 2 mg | 2.4 mg(winner) |
| Injection Frequency(times per week) | Once weekly subcutaneous injection | Once weekly subcutaneous injection |
| Active Ingredient Concentration Range(mg) | 0.25-2.4 mg weekly injection | — |
| FDA Approval Year | 2017(winner) | 2021 |
| FDA Approval Year(year) | 2017 (diabetes)(winner) | 2021 (weight management) |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | — |
| FDA Approval Date | December 2017 | — |
| Primary Indication | Type 2 Diabetes | Weight Loss & Obesity |
| Cardiovascular Benefits | Proven in diabetic patients | Proven in overweight/obese patients |
| Typical Insurance Coverage | Widely covered for diabetes | Limited coverage for weight loss |
| Number of Dose Strengths Available(strengths) | 4 | 5(winner) |
| Active Ingredient | Semaglutide (GLP-1 receptor agonist) | Semaglutide (GLP-1 receptor agonist) |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | 25-40% |
| Nausea Incidence in Clinical Trials(% of patients) | 10-15% (at 1mg dose)(winner) | 25% (at 2.4mg dose) |
| Injection Frequency(times per week) | 1 | 1 |
| Injection Schedule(per week) | Once weekly | — |
| Time to Maintenance Dose(weeks) | 12(winner) | 16 |
| HbA1c Reduction in Diabetics(percentage points) | 1.5-2.0(winner) | 0.5-1.0 |
| Active Ingredient Mechanism | GLP-1 receptor agonist (single pathway) | — |
| Number of Dose Strengths Available(options) | 3 | — |
| Time on Market(years) | 9 years | — |
| Insurance Coverage Approval Rate(% of major US insurers) | 85-95% (diabetes indication)(winner) | 35-45% (weight loss coverage limited) |
| Cardiovascular Outcome Reduction (CVOT)(% risk reduction) | 26% MACE reduction (SUSTAIN-6) | Data pending from SELECT trial |
| Cardiovascular Event Risk Reduction(%) | 26% (SUSTAIN-6 trial, n=3,297) | — |
| Time to Noticeable Weight Loss(weeks) | 8-12 weeks | 4-8 weeks(winner) |
| Insurance Coverage Rate (Non-Diabetic Use)(% of plans) | 50-65% (off-label)(winner) | 10-20% (excluded as cosmetic) |
| Active Ingredient Bioequivalence(% identical) | 100% semaglutide | — |
| Nausea Incidence Rate(%) | 40% at 1.0 mg dose | — |
| HbA1c Reduction(percentage points) | 1.5-2.0 points | — |
| Clinical Trial Sample Size(participants) | 3,297 (SUSTAIN-6) | — |
OzempicWegovyShow 2 more attributes
Show 1 more attribute
Pros & Cons
10 pros·5 cons across both
Ozempic
Pros
Cons
Wegovy
Pros
Cons
Frequently Asked Questions
5 questions
While Ozempic can produce weight loss as a side effect, it is not FDA-approved for weight loss in non-diabetic patients. Using it off-label for weight loss is common but should only be done under physician supervision. Wegovy is the FDA-approved option specifically designed for chronic weight management in non-diabetic individuals.
Both contain the same active ingredient (semaglutide) and work identically at the molecular level. The primary differences are their FDA-approved indications, maximum approved doses, and marketing purposes. Ozempic is indicated for type 2 diabetes, while Wegovy is indicated for chronic weight management.
Both medications have similar side effect profiles, with gastrointestinal issues (nausea, vomiting, constipation, diarrhea) being most common in 25-40% of users. Side effects typically diminish after the first few weeks as the body adjusts. Individual tolerance varies, and discussing potential side effects with your doctor is essential.
Wegovy is more expensive primarily due to insurance coverage differences. Ozempic has better insurance coverage for diabetic patients (a larger, established patient population), while Wegovy's weight loss indication has limited insurance coverage in most plans, forcing patients to pay out-of-pocket at higher costs. The medications themselves cost similarly to produce.
These are chronic disease management medications. For type 2 diabetes patients (Ozempic), discontinuation typically results in blood glucose levels returning to pre-treatment levels. Similarly, weight loss achieved with Wegovy is often regained after stopping the medication. Long-term use is usually recommended to maintain benefits, though individual circumstances vary.
Resources & Learn More
Curated sources to dive deeper
Where to Buy
As an Amazon Associate I earn from qualifying purchases. Other links on this page may also earn us a commission, at no extra cost to you. Learn more about our affiliate disclosure
Wikipedia
Explore More
Related comparisons and categories